ANABAnaptysBio, Inc.
$45.97+231% 1Y
$45.97
$13.9752 weeks$69.82
The financials
AnaptysBio, Inc. by the numbers
AnaptysBio, Inc. (ANAB) reported revenue of $27M in Q2 2026 (quarter ended Jun 30, 2026), up 23% from the same quarter a year earlier. That came with net income of $184M (669% of revenue). For the full year FY2025, revenue was $235M (+157% year on year) and net income −$13M. Its largest product in Q3 2025 (quarter ended Sep 30, 2025) was Anaptys Bio Generated Anti PD1 Jemperli Dostarlimab at $50M, 100% of the disclosed total, well ahead of Transaction Service at 0.2%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $27M | $22M | +23% |
| Operating income | $67M | −$26M | to a profit |
| Net income | $184M | −$39M | to a profit |
| Diluted EPS | $5.34 | −$1.34 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Anaptys Bio Generated Anti PD1 Jemperli Dostarlimab | $50M | 100% |
| Transaction Service | $100K | 0.2% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $100.0K (-100%)
Transaction Service grew 0.00% year on yearLicense -100% year on year
Segment Latestquarter on quarteryear on year
- Transaction Service$100.0K$100.0Kquarter on quarter n/ayear on year 0.00%n/a0.00%
- Anaptys Bio Generated Anti PD1 Jemperli Dostarlimab$0.00$0.00quarter on quarter -100%year on year n/a-100%n/a
- License$0.00$0.00quarter on quarter n/ayear on year -100%n/a-100%
On our screens:Most shorted stocks